Some regulators of plant growth and differentiation have been shown to induce the differentiation of several human myeloid leukemia cells, and might be effective as differentiation inducers to control acute myelogenous leukemia cells. In this study, the growth-inhibiting and differentiation-inducing effects of jasmonates on human myeloid leukemia cells were examined. Several myeloid leukemia cells were cultured with methyl jasmonate (MJ) and its derivatives. Cell differentiation was determined by nitroblue tetrazolium-reducing activity, morphological changes, a-naphthyl acetate esterase activity and expression of differentiation-associated surface antigens. MJ induced both monocytic and granulocytic differentiation of HL-60 cells. MJ activated mitogen-activated protein kinase (MAPK) in the cells before causing myelomonocytic differentiation. MAPK activation was necessary for MJ-induced differentiation, since PD98059, an inhibitor of MAPK kinase, suppressed the differentiation induced by MJ. MJ also induced the differentiation of other human leukemia cell lines. Introduction of a double bond at the 4,5-position greatly enhanced the differentiationinducing activity of MJ. MJ and its derivatives potently induce the differentiation of some myelomonocytic leukemia cells. One novel derivative is a particularly promising therapeutic agent for the treatment of leukemia.
Introduction
Regulators that play an important role in the differentiation and development of plants or invertebrates may also affect the differentiation of human normal and malignant cells through a common or different signal transduction system, and might be clinically useful for treating some types of cancer. Some regulators of plant growth and differentiation have been shown to induce the differentiation of several human myeloid leukemia cells, 1, 2 and might be effective as differentiation inducers to control acute myelogenous leukemia cells.
Compounds derived from the oxidative metabolism of polyunsaturated fatty acids are synthesized in response to external stimuli and play important roles in controlling diverse processes in both animals and plants. Members of the eicosanoid family of lipid mediators have been extensively studied with respect to their function in the regulation of cell differentiation, immune responses and homeostasis in animal systems, including normal and malignant hematopoietic cells. 3 In plants, oxygenated derivatives of polyunsaturated fatty acids also participate in the regulation of many defense-related and developmental processes. Jasmonates are potent lipid regulators in plants that play pivotal roles in their biological activities. 4, 5 These findings are reminiscent of some of the roles of wellknown mediators in animals, most notably prostaglandins (PGs). Some PGs enhance the differentiation of human myeloid leukemia cells, although their differentiation-inducing activities are not so prominent. [6] [7] [8] However, it is still possible that some PG analogs and their related compounds may potently induce the differentiation of leukemia cells. A recent report indicated that methyl jasmonate (MJ) inhibits the growth of some lymphoid malignant cells in vitro and in vivo.
9 MJ also affected calcium signaling by activating Ca 2 þ -ATPase in rat slow-twitch skeletal muscle. 10 These results prompted us to examine whether MJ and its derivatives could affect the differentiation of human myelogenous leukemia cells.
Materials and methods

Materials
MJ, dihydrojasmone and 1a,25-dihydroxyvitamin D 3 (VD 3 ) were purchased from Wako Pure Chemical Industry (Osaka, Japan). MJ derivatives ( Figure 1 ) were synthesized as described previously. [11] [12] [13] [14] [15] Nitroblue tetrazolium (NBT), 8-chloro-adenosine 3 0 ,5 0 -cyclic monophosphate (8-Cl-cAMP) and all-trans retinoic acid (ATRA) were purchased from Sigma Chemicals (St Louis, MO, USA). PD98059 was obtained from Calbiochem (La Jolla, CA, USA).
Cells and cell culture
Human myeloid leukemia and cancer cell lines were cultured in suspension in RPMI1640 medium (Sigma Chemicals) supplemented with 10% fetal bovine serum at 371C in a humidified atmosphere of 5% CO 2 in air. In experiments where cells were treated with PD98059, cells were cultured with the inhibitor 16 h before the start of measurements. At 0 h, PD98059-treated cells were cultured with differentiation inducers, and the same concentration of PD98059 was again added to the cultures. At 16 h, PD98059 was added again, and these three successive additions of PD98059 had no apparent growth-inhibitory effect. 16 
Assay of cell growth and properties of differentiated cells
The cell number was counted in a model Z1 Coulter Counter (Beckman Coulter Electronics, Luton, UK). To assay differentiation, leukemia cells (5 Â 10 4 /ml) were cultured with various concentrations of a drug for 4-6 days. NBT reduction and nonspecific esterase activity were determined by the methods described previously. 16 Morphological differentiation was examined in cell smears stained with May-Grü nwald-Giemsa. CD expression was analyzed by indirect immunofluorescent staining and flow cytometry using an Epics XL flow cytometer (Beckman Coulter) as described elsewhere. 1, 16 Simultaneous detection of DNA synthesis and expression of CD11b Cells were cultured with or without inducer for 4 days and then labeled with 30 mM bromodeoxyuridine (BrdU) for 2 h. After washing with phosphate-buffered saline, cells were incubated with PE-labeled antibody for CD11b. After fixation with 1% paraformaldehyde-0.01% Tween 20 overnight at 41C, cells were incubated with FITC-labeled antibody for BrdU and then analyzed by a flow cytometer, as described previously. 17 Assays of cyclic AMP content and mitogen-activated protein kinase (MAPK) activity Intracellular cyclic AMP content was determined by an immunoassay kit (R&D Systems, Inc., Minneapolis, MN, USA). MAPK activity was measured by the phosphorylation of Elk1, one of the in vivo targets of MAPK. The kinase assay was performed using a p44/42 MAP Kinase Assay Kit (New England Biolabs, Beverly, MA, USA) according to the manufacturer's instructions.
Analysis of the effects of combinations of drugs and statistical evaluation
The interaction of the two compounds was quantified by determining the combination index according to the classic isobogram equation. 18 Statistical analyses were performed using an unpaired two-tailed Student's t-test.
Results
Effects of MJ on the growth and differentiation of myelomonocytic leukemia cells
MJ was examined with regard to its ability to inhibit the growth of several human malignant cell lines (see supplementary information, Supplementary Table A) . The growth-inhibitory effects of MJ were evaluated by determining the concentration required to reduce the cell number to half that in the untreated culture within 6 days (IC 50 ). Leukemia cells were more sensitive than solid tumor cells and HL-60 cells were the most sensitive to MJ with regard to the inhibition of cell growth. Growth of the cells was significantly inhibited by MJ (Figure 2a ). MJ significantly induced NBT reduction, a typical marker of myelomonocytic differentiation, in leukemia cells (Figure 2b ). MJ also induced the morphologic differentiation of HL-60 cells into granulocytes with some properties of monocytes, such as monocytic granules (Figure 3b ), and this was confirmed by the expression of both the monocyte-specific surface antigen CD14 and granulocyte-specific CD15 in HL-60 cells (Figure 2d ). The monocytic nature was also indicated by the induction of a-naphthyl acetate esterase activity, a monocyte-specific marker (Figures 2c and 3d ). When HL-60 cells were cultured with MJ, the CD11b-positive cells did not incorporate BrdU and the BrdU-labeled cells did not express CD11b, indicating that the differentiated leukemia cells do not proliferate (Figure 2e ). These results indicate that MJ did not selectively kill immature HL-60 cells, but induce differentiation to mature cells.
Next, we examined the effects of MJ on other myelomonocytic leukemia cells. MJ also induced NBT reduction in other leukemia cells, and HL-60 cells were the most sensitive to MJ with respect to its differentiation-inducing effect (see supplementary information, Supplementary Figure A) . Structures of jasmonate derivatives.
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Effects of other inducers on the MJ-induced differentiation of leukemia cells
ATRA is a potent inducer of the granulocytic differentiation of HL-60 cells and has been used successfully to treat acute promyelocytic leukemia. 19, 20 The NBT-reducing activity induced by MJ was more than additively enhanced by the addition of ATRA (Figure 4a ). Morphological changes in granulocytes were also enhanced by MJ plus ATRA (data not shown). VD 3 induces the monocytic differentiation of HL-60 cells. 21 The effects of the combination of MJ and VD 3 were determined using isobogram equation. 18 The combination index was 0.46, indicating synergism. VD 3 and MJ synergistically induced NBT reduction in HL-60 cells (Figure 4b) , and other inducers such as dimethyl sulfoxide, cotylenin A and tumor necrosis factor-a also had cooperative effects with MJ in inhibiting growth and inducing the differentiation of HL-60 cells (data not shown).
Cyclic AMP is not a mediator of MJ-induced differentiation
PGs increase the cyclic AMP content in some cells and cyclic AMP may act as a second messenger. The differentiation of HL-60 cells was stimulated by cyclic AMP, which is more effective than PGE 2 or PGD 2 as an inducer. 2, 8, 22, 23 The cyclic AMP content was not significantly affected by MJ within 2 days, and it gradually increased thereafter (Figure 5a ). 8-Cl-cAMP induced the granulocytic differentiation-associated marker CD15, but it did not induce monocytic differentiation markers such as CD14 (Figure 5b ) and a-naphthyl acetate esterase activity. These findings indicate that cyclic AMP induced the granulocytic differentiation of HL-60 cells, whereas MJ induced both monocytic and granulocytic differentiation of the cells ( Figures  2 and 3) , suggesting that cyclic AMP does not mediate an early event in MJ-induced differentiation, although we cannot eliminate the possibility that it may mediate part of the MJ effects.
MAPK activation by MJ and blockade of differentiation by PD98059
Some inducers activate MAPK in HL-60 cells before inducing granulocytic differentiation, and this activation is needed to elicit differentiation and growth arrest. 24 Treatment with PD98059, a specific inhibitor of MAPK kinase (MEK) phosphorylation and activation, 25 resulted in the loss of activated MAPK from HL-60 cells and blockade of the differentiation of HL-60 cells. 24 MJ significantly increased MAPK activity by 12 h, and this enhancement persisted for 24 h (Figure 5c ). The enhancement induced by MJ was more prominent than that induced by ATRA. The increased MAPK activity was reduced by pretreatment with PD98059. This inhibitor also suppressed the NBT reduction induced by MJ (Figure 5e ), suggesting that MAPK activation is required for MJ-induced differentiation.
To assess the involvement of other signal transduction pathways which are thought to be related to differentiation in the mechanism of action of MJ, we examined the effects of 
Effects of MJ derivatives on the growth and differentiation of myelomonocytic leukemia cells
To find more effective compounds, we synthesized various derivatives of MJ ( Figure 1 ) and examined their differentiationinducing (Figure 6a ) and growth-inhibiting effects (Table 1) on HL-60 cells. Of the compounds tested, compound V (methyl 4,5-didehydrojasmonate) was the most effective for inhibiting growth and inducing NBT reduction in HL-60 cells. The compound also effectively induced MAPK activity in a concentration-dependent manner (Figure 5d ). This derivative was about 30 times more potent than MJ on a molar basis, and the other derivatives were also more potent than MJ. This derivative was effective at inducing the differentiation of all of the other leukemia cell lines tested, and it also had synergistic effects with ATRA and VD 3 ( Figure 6b and data not shown).
Discussion
The molecular mechanisms of jasmonate action in plants are only partially understood. Jasmonates induce MAPK pathways (major pathways by which extracellular stimuli are transduced into intracellular responses) in rice, suggesting that MAPKs play important signaling roles in plants, 27, 28 although MAPK pathways are not considered as a general target of jasmonate action in plants. 29 The role of the MAPK pathway in the induction of differentiation of HL-60 leukemia cells is not entirely clear, but the phosphorylation and activation of MAPK has been reported to occur after the addition of several differentiation-inducing agents. 16, 24, 30 Jasmonates activated MAPK in HL-60 cells before inducing myelomonocytic differentiation and cell cycle arrest. MAPK activation by MEK was necessary for jasmonate-induced differentiation in studies using PD98059 to block MEK phosphorylation. Several inhibitors of other signal transduction pathways did not affect jasmonate-induced differentiation. Cyclic AMP promotes the differentiation of some tumor cells including HL-60 cells, but jasmonates do not stimulate intracellular cyclic AMP accumulation in the early stages of the differentiation of HL-60 cells. These results suggest that jasmonates induce the myelomonocytic differentiation of leukemia cells primarily through the activation of MAPK, although we cannot eliminate the possible involvement of other signal transduction pathways. A recent report shows that MJ induces activation of stress-regulated c-Jun N-terminal kinase and p38 protein kinase in lymphoid cells. 31 Further experimentation is necessary to understand the role of MAPKs on anticancer action of MJ.
Our final goal is perform clinical trials of jasmonate derivatives in differentiation therapy for hematopoietic malignancies, either alone or in combination with other differentiation inducers so that their doses can be reduced. Jasmonate and its analogs are used as flavorings in foods and in cosmetics, and MJ was therapeutically effective in an animal model of lymphoma, 9 suggesting that these compounds may be clinically useful. These results prompted us to examine its analogs to n Po0.05, nn Po0.01.
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identify some that may be more effective at inducing the differentiation of leukemia cells. We found that the introduction of a double bond at the 4,5-position greatly enhanced differentiation-inducing activity, although its growth-inhibitory activity in rice and radish is little affected by this modification. 12 These results suggest that the most effective analog depends on the cell type and/or species. VD3 has been used to treat myelodysplastic syndromes and smoldering leukemia, but it is less effective than cytosine arabinoside because it causes hypercalcemia at therapeutic dosages. 32 An approach that has been developed to overcome this disadvantage in the clinical setting is to reduce the effective concentration of VD 3 in combination with other differentiation inducers. MJ and its analogs synergistically enhanced growth inhibition and differentiation in leukemia cells in combination with suboptimal concentrations of VD 3 . It decreased the effective concentration of VD 3 to on the order of 10 À10 M. Therefore, the combination of VD 3 and jasmonates may be useful in the treatment of some hematopoietic malignancies. However, these findings using human leukemia cell lines do not completely reflect the situation in patients with acute leukemia. Further experiments using freshly isolated primary leukemic cells and SCID mice models inoculated with human leukemia cells are necessary to develop a new strategy for differentiation therapy against leukemia.
Since several plant hormones and their analogs induce cell cycle arrest and inhibit human cell proliferation, 1,9,33-36 these compounds may be therapeutic agents against human malignancies. 
